Key facts
- Neosoma (Decision/Risk Analysis)’s last known valuation is $28.0M (Mar 2026).
- It has raised $8.9M; the latest was Seed Round ($3.5M) in Mar 2026.
- Notable investors include Alliance of Angels, Filter Fund, Octane (California), TCA Venture Group.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Neosoma (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for Neosoma (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neosoma (Decision/Risk Analysis)
Developer of an image analysis technology designed to routinely acquire magnetic resonance imaging sequences. The company's technology facilitates practitioners to analyze the magnetic resonance imaging sequences and provides an automated response assessment about tumors that are irregular in shape, such as glioblastoma, enabling doctors and clinicians to instantaneously access the status of the disease through digital images.
- Sector
- Healthcare
- HQ
- Groton, MA, United States
- Founded
- 2019
- Employees
- 11
- Website
- neosomainc.com/
- Ownership
- Privately Held (backing)
Neosoma (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neosoma (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neosoma (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.